Introduction
Materials and methods
Material collection
Collecting active ingredients and targets of SCL
Screening of targets for IUA
Network construction
Active ingredient-target network construction for SCL
Constructing a network of potential targets
Construction of component-target-pathway networks
GO and KEGG enrichment analyses
Molecular docking
Cell culture
Cell counting Kit-8 assay
Western blot analysis
Statistical analysis
Results
Active compounds and potential targets of SCL against IUA
PPI network of common targets
NO. | Uniprot ID | Gene symbol | Protein name | Degree | |
---|---|---|---|---|---|
1 | P31749 | AKT1 | RAC-alpha serine/threonine-protein kinase | 72 | |
2 | P04637 | TP53 | Cellular tumor antigen p53 | 69 | |
3 | P15692 | VEGFA | Vascular endothelial growth factor A | 67 | |
4 | P12931 | SRC | Proto-oncogene tyrosine-protein kinase Src | 64 | |
5 | P42574 | CASP3 | Caspase 3 | 64 | |
6 | P01112 | HRAS | HRas Proto-Oncogene, GTPase | 60 | |
7 | P00533 | EGFR | Epidermal growth factor receptor | 59 | |
8 | P03372 | ESR1 | Estrogen receptor | 56 | |
9 | Q16665 | HIF1A | Hypoxia-inducible factor 1-alpha | 56 | |
10 | P42345 | MTOR | Serine/threonine-protein kinase mTOR | 53 | |
11 | P37231 | PPARG | Peroxisome proliferator activated receptor gamma | 51 | |
12 | P35354 | PTGS2 | Prostaglandin G/H synthase 2 | 50 | |
13 | P01100 | FOS | Transcription factor AP-1 | 49 | |
14 | P14780 | MMP9 | Matrix metalloproteinase-9 | 48 | |
15 | Q07817 | BCL2L1 | Apoptosis regulator Bcl-2 | 47 |
GO enrichment analysis
KEGG pathway analysis
ID | Term | Count | Fold Enrichment | Gene | P Value |
---|---|---|---|---|---|
hsa05200 | Pathways in cancer | 42 | 7.60 | GSK3B, CDKN1A, HSP90AB1, FLT3, PIK3R1, PTGS2, HIF1A, RELA, EGFR, IGF1R, CASP9, CASP8, RXRA, TERT, CASP3, AKT1, PRKACA, HRAS, TGFB1, NOS2, STAT1, MMP2, PRKCA, FOS, F2, MMP9, ESR1, MTOR, PTK2, ESR2, VEGFA, AR, CDK6, IFNG, KIT, CDK2, BAX, PPARG, CALM1, MET, TP53, BCL2L1 | 5.57E-27 |
hsa05417 | Lipid and atherosclerosis | 25 | 11.17 | GSK3B, HSP90AB1, SRC, PIK3R1, RELA, ICAM1, CASP9, CASP8, RXRA, CASP3, AKT1, APOB, HRAS, MMP3, PRKCA, FOS, MAPK14, MMP9, PTK2, TNFRSF1A, BAX, PPARG, CALM1, TP53, BCL2L1 | 5.19E-19 |
hsa05167 | PI3K-Akt signaling pathway | 25 | 6.78 | GSK3B, CDKN1A, HSP90AB1, FLT3, PIK3R1, RELA, EGFR, PIK3CG, IGF1R, CASP9, RXRA, KDR, AKT1, HRAS, PRKCA, MTOR, PTK2, VEGFA, CDK6, KIT, CDK2, PKN1, MET, TP53, BCL2L1 | 5.37E-14 |
hsa01522 | Kaposi sarcoma-associated herpesvirus infection | 24 | 11.88 | GSK3B, CDKN1A, STAT1, SRC, PIK3R1, FOS, PTGS2, MAPK14, HIF1A, MTOR, PIK3CG, RELA, ICAM1, TNFRSF1A, VEGFA, CASP9, CASP8, CDK6, CASP3, BAX, AKT1, CALM1, HRAS, TP53 | 8.08E-19 |
hsa05163 | Human cytomegalovirus infection | 23 | 9.82 | GSK3B, CDKN1A, SRC, PRKCA, PIK3R1, PTGS2, MAPK14, EGFR, MTOR, RELA, PTK2, TNFRSF1A, VEGFA, CASP9, CASP8, CDK6, CASP3, BAX, AKT1, CALM1, PRKACA, HRAS, TP53 | 3.36E-16 |
hsa05205 | Proteoglycans in cancer | 22 | 10.31 | CDKN1A, TGFB1, SRC, MMP2, PRKCA, PIK3R1, MAPK14, HIF1A, ESR1, MMP9, EGFR, MTOR, PTK2, IGF1R, VEGFA, CASP3, KDR, AKT1, PRKACA, HRAS, MET, TP53 | 6.83E-16 |
hsa05215 | Human papillomavirus infection | 21 | 6.09 | GSK3B, CDKN1A, STAT1, PIK3R1, PTGS2, EGFR, MTOR, RELA, PTK2, TNFRSF1A, VEGFA, CASP8, CDK6, TERT, CASP3, CDK2, BAX, AKT1, PRKACA, HRAS, TP53 | 8.21E-11 |
hsa01521 | Chemical carcinogenesis - receptor activation | 19 | 8.61 | HSP90AB1, SRC, CHRNA7, PRKCA, PIK3R1, FOS, ADRB2, ESR1, EGFR, MTOR, RELA, ESR2, VEGFA, AR, RXRA, CYP1B1, AKT1, PRKACA, HRAS | 2.94E-12 |
hsa04151 | Endocrine resistance | 18 | 17.64 | CDKN1A, SRC, MMP2, PIK3R1, FOS, MAPK14, ESR1, MMP9, EGFR, MTOR, PTK2, ESR2, IGF1R, BAX, AKT1, PRKACA, HRAS, TP53 | 6.78E-17 |
hsa05160 | Hepatitis C | 18 | 11.01 | GSK3B, CDKN1A, STAT1, PIK3R1, EGFR, RELA, TNFRSF1A, CASP9, CASP8, RXRA, CDK6, IFNG, CASP3, CDK2, BAX, AKT1, HRAS, TP53 | 2.37E-13 |
hsa05222 | Hepatitis B | 18 | 10.67 | CDKN1A, TGFB1, STAT1, SRC, PRKCA, PIK3R1, FOS, MAPK14, MMP9, RELA, CASP9, CASP8, CASP3, CDK2, BAX, AKT1, HRAS, TP53 | 4.00E-13 |
hsa05161 | Human immunodeficiency virus 1 infection | 18 | 8.15 | PRKCA, PIK3R1, FOS, MAPK14, MTOR, RELA, PTK2, TNFRSF1A, CASP9, CASP8, CASP3, CHEK1, CDK1, BAX, AKT1, CALM1, HRAS, BCL2L1 | 3.22E-11 |
hsa05418 | Fluid shear stress and atherosclerosis | 17 | 11.75 | HSP90AB1, SRC, MMP2, PIK3R1, FOS, MAPK14, MMP9, RELA, PTK2, ICAM1, TNFRSF1A, VEGFA, IFNG, KDR, AKT1, CALM1, TP53 | 4.97E-13 |
hsa05212 | Prostate cancer | 16 | 15.84 | GSK3B, CDKN1A, HSP90AB1, MMP3, PIK3R1, MMP9, EGFR, MTOR, RELA, IGF1R, CASP9, AR, CDK2, AKT1, HRAS, TP53 | 3.30E-14 |
hsa05207 | EGFR tyrosine kinase inhibitor resistance | 15 | 18.24 | GSK3B, SRC, PRKCA, PIK3R1, EGFR, MTOR, IGF1R, VEGFA, AXL, KDR, BAX, AKT1, HRAS, MET, BCL2L1 | 3.53E-14 |
hsa04919 | Small cell lung cancer | 15 | 15.66 | CDKN1A, NOS2, PIK3R1, PTGS2, RELA, PTK2, CASP9, RXRA, CDK6, CASP3, CDK2, BAX, AKT1, TP53, BCL2L1 | 3.21E-13 |
hsa05170 | Thyroid hormone signaling pathway | 15 | 11.91 | NCOA2, GSK3B, STAT1, SRC, PRKCA, PIK3R1, HIF1A, ESR1, MTOR, CASP9, RXRA, AKT1, PRKACA, HRAS, TP53 | 1.53E-11 |
hsa04926 | Relaxin signaling pathway | 15 | 11.17 | TGFB1, NOS2, SRC, MMP2, PRKCA, PIK3R1, FOS, MAPK14, MMP9, EGFR, RELA, VEGFA, AKT1, PRKACA, HRAS | 3.69E-11 |
hsa05210 | Pancreatic cancer | 14 | 17.69 | CDKN1A, TGFB1, STAT1, PIK3R1, EGFR, MTOR, RELA, VEGFA, CASP9, CDK6, BAX, AKT1, TP53, BCL2L1 | 5.03E-13 |
hsa05165 | Colorectal cancer | 13 | 14.52 | GSK3B, CDKN1A, TGFB1, PIK3R1, FOS, EGFR, MTOR, CASP9, CASP3, BAX, AKT1, HRAS, TP53 | 5.19E-11 |